On 23 December, the French regulatory authorities, AFFSAPS, announced that there is no identifiable causal relationship between cancer and breast implants from the French company PIP, Poly Implant Prothèse. Based on the available knowledge, the Danish National Board of Health and the Danish Medicines Agency recommend not to remove PIP implants as a routine measure.
The use of PIP breast implants was prohibited in April 2010 because the risk of rupture of these implants is higher compared to other similar breast implants. The implants concerned come from Poly Implant Prothèse (PIP). They are labelled IMGHC-TX, IMGHC-MX and IMGHC-LS and are manufactured in 2001 or later. The products have also been sold under the name Rofil.
Since they were prohibited in 2010, the Danish health authorities have followed the development closely.
Women who have received breast implants are advised to contact the responsible hospital or clinic, or their own doctor, if the implants cause problems, e.g. if there are signs of rupture.
The use of PIP implants in Denmark has been limited, and the Danish Medicines Agency has knowledge of a total of 59 implants, but there could be slightly more. The vast majority were sold to "Privatkliniken", residing at H.C. Andersens Boulevard 42, Copenhagen. This clinic closed in 2008.
The Danish health authorities closely follow the safety conditions of all breast implants, including PIP implants, based on which the authorities make the necessary scientific assessments and recommendations.
Patients who believe they have been harmed by PIP implants are advised to report it to the Danish Patient Insurance Association.